EUCTR2020-000754-97-GB进行中（未招募）1 期
Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness: a randomized controlled trial. - The ASTUTE Trial
niversity Hospitals Bristol and Weston NHS Foundation Trust0 个研究点目标入组 400 人开始时间: 2020年9月11日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must:
- •(a) present with active sight-threatening ANIU in either or both eyes and who are taking oral prednisolone >5mg/day or being started on steroids >5mg/day, or
- •(b) those in remission taking >5mg/day of oral prednisolone and other immunomodulatory therapy drugs as required.
- •In the subgroup presenting with new active disease, remission will be induced with high dose oral prednisolone; oral prednisolone will be tapered to less than or equal to 5mg/day over 16 weeks in both groups. The treatment goal in the treatment run-in is the same for both groups, i.e. disease remission with less than or equal to 5mg/day oral prednisolone. If achieved by the end of the treatment run-in, participants will be eligible for randomisation.
- •To be eligible for the trial, including the 'treatment run-in', all of the following must apply:
- •1. Participant is aged 18 years or over;
- •2. Participant has: (a) active sight threatening ANIU (active inflammatory chorioretinal lesions OR abnormal central macular thickness (CMT) OR evidence of retinal vasculitis OR vitreous haze >0.5) and is being prescribed (already taking or being started on, if newly presenting with ANIU) oral prednisolone >5.0mg/day; OR (b) has controlled ANIU and is being prescribed oral prednisolone >5.0mg/day;
- •3. Women must have a negative pregnancy test and be willing to use effective contraception* for the duration of the participation in the trial and for 5 months after, or be surgically sterile or post-menopausal for >12 months;
- •4. Participant is able to provide informed consent.
- •* this includes: progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide cap, diaphragm or sponge with spermicide, combined (eostrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation: (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, sexual abstinence.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 400
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •A participant may not enter the trial, including the 'treatment run-in' if any of the following apply:
- •1. Participant has controlled ANIU and is maintained on corticosteroids =5.0 mg/day at the time of screening;
- •2. Participant has systemic disease (whether associated with ANIU or not) that is being treated with steroids and requires >5mg/day oral prednisolone;
- •3. Participant has untreated or active tuberculosis;
- •4. Participant has severe infection, sepsis or opportunistic infection;
- •5. Participant has uncontrolled glaucoma;
- •6. Participant has multiple sclerosis;
- •7. Participant is HIV positive;
- •8. Participant has hepatitis B or hepatitis C
- •9. Participant has syphilis
- •10. Participant has Lyme disease
- •11. Participant has Behcet’s disease
- •12. Participant has toxoplasmosis chorioretinitis
- •13. Participant has heart failure (NYHA III/IV)
- •14. Participant has been diagnosed with cancer <5 years ago
- •15. Participant is undergoing monitoring for recurrence of cancer / tumour growth where their oncologist has concern that a TNFalpha inhibitor would be contraindicated
- •16. Participant is taking another biologic drug;
- •17. Participant has taken an anti-TNF drug within the previous 90 days (anakinra and abatacept are contraindicated);
- •18. Participant has had an Iluvien® implant within the previous 18 months and has controlled ANIU, or has had an Iluvien® implant within the previous 12 weeks regardless of whether ANIU is active or controlled;
- •19. Participant has had an Ozurdex® implant, or an intravitreal steroid injection, or periocular steroid within the previous 12 weeks regardless of whether ANIU is active or controlled;
- •20. Participant is pregnant;
- •21. Participant has a known allergy or hypersensitivity to adalimumab or any of its excipients;
- •22. Participant is taking part in another interventional study.
研究者
相似试验
已完成
4 期
Study of Combination Therapy of Adalimumab and an Immunomodulator for Crohn's Disease(Diamond study)s diseaseCrohn's diseaseJPRN-UMIN000005146Department of Internal Medicine, School of Medicine, Keio University200
招募中
不适用
Relation between Efficacy of Adalimumab and Pharmacokinetics in Ulcerative colitis.lcerative colitisJPRN-UMIN000013788Department of Medicine, Shiga University of Medical Science40
已完成
不适用
Effect of adacolumn and adalimumab combination therapy for the active stage Crohn's diseases diseaseCrohn's diseaseJPRN-UMIN000007047Yamaguchi University Graduate School of Medicine Department of Gastroenterology and Hepatology40
尚未招募
2 期
The effect of Adalimumab in the treatment of patients with chronic schizophreniaSchizophrenia.SchizophreniaIRCT20090117001556N126Tehran University of Medical Sciences50
进行中（未招募）
1 期
English Study evaluating safety and efficacy of mepolizumab in the treatment of COPD patients with frequent exacerbations.Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbationsMedDRA version: 18.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2013-004297-98-NLGlaxoSmithKline Research & Development Ltd660